Sorriso Pharmaceuticals — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Sorriso Pharmaceuticals is a private, preclinical-stage biotech founded in 2018 and based in Cambridge, USA. The company is pioneering a platform for orally delivered single-domain antibodies ('Vorabodies') aimed at treating autoimmune and inflammatory diseases, with a lead program in ulcerative colitis. Recent positive Phase 1b data for SOR102 and a publication in The Lancet Gastroenterology & Hepatology validate its innovative approach. Sorriso's technology promises targeted, local therapy with manufacturing and stability advantages over traditional injectable antibodies.

Autoimmune DiseasesInflammatory DiseasesGastroenterology

Technology Platform

Platform for engineering orally delivered single-domain antibodies ('Vorabodies') with high specificity, tissue localization, protease stability, and scalable yeast-based manufacturing.

Opportunities

The large and growing IBD market, dominated by injectable biologics, presents a major opportunity for a convenient, effective oral therapy.

Success with SOR102 could validate the platform for expansion into other immune-mediated diseases via oral or inhaled delivery, creating multiple pipeline opportunities.

Risk Factors

Key risks include clinical failure of the novel oral antibody approach in larger trials, intense competition from established injectable biologics and other oral therapies, and dependence on external financing as a pre-revenue private company.

Competitive Landscape

Sorriso competes in the crowded IBD space against dominant injectable anti-TNF and anti-IL-23 biologics (e.g., Humira, Stelara, Skyrizi) and oral small molecules like JAK inhibitors (Xeljanz, Rinvoq). Its differentiation hinges on combining the specificity of antibodies with the convenience of oral delivery.

More companies in Biologics / Biosimilars →More companies in United States →